We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EyeGate

News List

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules firstwordpharma
August 12, 2021
EyeGate Pharmaceuticals, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share.
Valeant Pharmaceuticals and EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product americanpharmaceuticalreview
February 22, 2017
Valeant Pharmaceuticals International and EyeGate Pharmaceuticals have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive,